EZH2 and central nervous system cancer: Whole genome sequencing showed the frequent incidence of histone H3 mutations in pediatric glioma patient samples and aberrant expression of EZH2 (enhancer of zeste homolog 2) and KDMs (lysine demethylases) in GBM patient samples [7, 10, 11].